Abstract
This study aimed to investigate the regulatory function of lncRNA RMRP in non-alcoholic fatty liver disease (NAFLD). In vitro and in vivo NAFLD models were constructed. Hematoxylin & Eosin (H&E) and Oil-Red O staining assays were conducted to observe the morphology and lipid accumulation in liver tissues. Triglycine (TG) secretion was detected by ELISA assay. The expression levels of RMRP, microRNA-206, PTPN1 (protein tyrosine phosphatase, non-receptor type 1), and their downstream genes were assessed by qRT-PCR and Western blot. The regulatory relationship among these molecules was determined by luciferase reporter and RNA pull-down assays. RMRP and PTPN1 were up-regulated, while miR-206 was down-regulated in the liver tissues of NAFLD patients and rat model. RMRP inhibition improved the pathological state and liver function-related indexes of liver lipid deposition in the liver tissues of NAFLD rats. RMRP inhibition alleviated steatosis and TG secretion in free fatty acids (FFA)-treated AML-12 cells. RMRP could bind to miR-206 and downregulate its expression. Meanwhile, RMRP inhibition attenuated lipid accumulation by downregulating the PTPN1-PP2ASP1-SREBP1C pathway. Furthermore, RMRP inhibited the miR-206/PTPN1-SREBP1C signaling pathway in NAFLD rats and FFA-treated AML-12 cells. RMRP inhibition prevented NAFLD progression in rats via targeting the miR-206/PTPN1 axis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated and/or analyzed during the current study are not publicly available due research design but are available from the corresponding author on reasonable request.
References
Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ (2017) Targeting noncoding RNAs in disease. J Clin Investig 127:761–771. https://doi.org/10.1172/jci84424
An JH, Chen ZY, Ma QL, Li YB, Shi FW (2020) Liraglutide improves atherosclerosis by regulating long non-coding RNA RMRP/miR-128-1-5P/Gadd45g axis. Eur Rev Med Pharmacol Sci 24:2725–2737. https://doi.org/10.26355/eurrev_202003_20545
Cao HL, Liu ZJ, Huang PL, Yue YL, Xi JN (2019) lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci 23:1012–1021. https://doi.org/10.26355/eurrev_201902_16988
Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332:1519–1523. https://doi.org/10.1126/science.1204265
Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377:2063–2072. https://doi.org/10.1056/NEJMra1503519
Gjorgjieva M, Sobolewski C, Dolicka D, Correia de Sousa M, Foti M (2019) miRNAs and NAFLD: from pathophysiology to therapy. Gut 68:2065–2079. https://doi.org/10.1136/gutjnl-2018-318146
Hammond SM (2015) An overview of microRNAs. Adv Drug Deliv Rev 87:3–14. https://doi.org/10.1016/j.addr.2015.05.001
Han Y, Cai Y, Lai X, Wang Z, Wei S, Tan K, Xu M, Xie H (2020) lncRNA RMRP prevents mitochondrial dysfunction and cardiomyocyte apoptosis via the miR-1-5p/hsp70 axis in LPS-induced sepsis mice. Inflammation 43:605–618. https://doi.org/10.1007/s10753-019-01141-8
Huang R, Bai C, Liu X, Zhou Y, Hu S, Li D, Xiang J, Chen J, Zhou P (2021) The p53/RMRP/miR122 signaling loop promotes epithelial-mesenchymal transition during the development of silica-induced lung fibrosis by activating the notch pathway. Chemosphere 263:128133. https://doi.org/10.1016/j.chemosphere.2020.128133
Hussen BM, Azimi T, Hidayat HJ, Taheri M, Ghafouri-Fard S (2021) Long non-coding RNA RMRP in the pathogenesis of human disorders. Fronti Cell Dev Biol 9:676588. https://doi.org/10.3389/fcell.2021.676588
Lin HY, Wang FS, Yang YL, Huang YH (2019) MicroRNA-29a suppresses CD36 to ameliorate high fat diet-induced steatohepatitis and liver fibrosis in mice. Cells 8:1298. https://doi.org/10.3390/cells8101298
Liu J, Tang T, Wang GD, Liu B (2019) LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease. Biosci Rep. https://doi.org/10.1042/bsr20181722
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262
Lu JF, Qi LG, Zhu XB, Shen YX (2020) LncRNA RMRP knockdown promotes proliferation and inhibits apoptosis in osteoarthritis chondrocytes by miR-206/CDK9 axis. Pharmazie 75:500–504. https://doi.org/10.1691/ph.2020.0591
Meng Q, Ren M, Li Y, Song X (2016) LncRNA-RMRP acts as an oncogene in lung cancer. PLoS ONE 11:e0164845. https://doi.org/10.1371/journal.pone.0164845
Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F (2016) NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol 65:1245–1257. https://doi.org/10.1016/j.jhep.2016.07.033
Paraskevopoulou MD, Hatzigeorgiou AG (2016) Analyzing MiRNA–LncRNA Interactions. Methods Mol Biol 1402:271–286. https://doi.org/10.1007/978-1-4939-3378-5_21
Rashid F, Shah A, Shan G (2016) Long non-coding RNAs in the cytoplasm. Gen Proteom Bioinform 14:73–80. https://doi.org/10.1016/j.gpb.2016.03.005
Shao Y, Ye M, Li Q, Sun W, Ye G, Zhang X, Yang Y, Xiao B, Guo J (2016) LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget 7:37812–37824. https://doi.org/10.18632/oncotarget.9336
Shimizu S, Ugi S, Maegawa H, Egawa K, Nishio Y, Yoshizaki T, Shi K, Nagai Y, Morino K, Nemoto K, Nakamura T, Bryer-Ash M, Kashiwagi A (2003) Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression. J Biol Chem 278:43095–43101. https://doi.org/10.1074/jbc.M306880200
Teng Y, Ding M, Wang X, Li H, Guo Q, Yan J, Gao L (2020) LncRNA RMRP accelerates hypoxia-induced injury by targeting miR-214-5p in H9c2 cells. J Pharmacol Sci 142:69–78. https://doi.org/10.1016/j.jphs.2019.07.014
Wang X, Peng L, Gong X, Zhang X, Sun R, Du J (2018) LncRNA-RMRP promotes nucleus pulposus cell proliferation through regulating miR-206 expression. J Cell Mol Med 22:5468–5476. https://doi.org/10.1111/jcmm.13817
Wong CM, Tsang FH, Ng IO (2018) Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol 15:137–151. https://doi.org/10.1038/nrgastro.2017.169
Wu H, Zhang T, Pan F, Steer CJ, Li Z, Chen X, Song G (2017) MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis. J Hepatol 66:816–824. https://doi.org/10.1016/j.jhep.2016.12.016
Yang F, Yang L, Li Y, Yan G, Feng C, Liu T, Gong R, Yuan Y, Wang N, Idiiatullina E, Bikkuzin T, Pavlov V, Li Y, Dong C, Wang D, Cao Y, Han Z, Zhang L, Huang Q, Ding F, Bi Z, Cai B (2017) Melatonin protects bone marrow mesenchymal stem cells against iron overload-induced aberrant differentiation and senescence. J Pineal Res 63:e12422. https://doi.org/10.1111/jpi.12422
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20. https://doi.org/10.1038/nrgastro.2017.109
Yuan P, Qi X, Song A, Ma M (2021) LncRNA MAYA promotes iron overload and hepatocyte senescence through inhibition of YAP in non-alcoholic fatty liver disease. J Cell Mol Med 25:7354–7366. https://doi.org/10.1111/jcmm.16764
Zhang SY, Huang SH, Gao SX, Wang YB, Jin P, Lu FJ (2019a) Upregulation of lncRNA RMRP promotes the activation of cardiac fibroblasts by regulating miR-613. Mol Med Rep 20:3849–3857. https://doi.org/10.3892/mmr.2019.10634
Zhang T, Hu J, Wang X, Zhao X, Li Z, Niu J, Steer CJ, Zheng G, Song G (2019b) MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway. J Hepatol 70:87–96. https://doi.org/10.1016/j.jhep.2018.08.026
Zhang Q, Wang J, Li H, Zhang Y, Chu X, Yang J, Li Y (2020) LncRNA Gm12664-001 ameliorates nonalcoholic fatty liver through modulating miR-295-5p and CAV1 expression. Nutr Metab 17:13. https://doi.org/10.1186/s12986-020-0430-z
Zhao XY, Xiong X, Liu T, Mi L, Peng X, Rui C (2018) Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nat Commun 9:2986. https://doi.org/10.1038/s41467-018-05383-2
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
MZ and JJY: study concepts, study design, literature research, experimental studies, manuscript preparation and editing; XFC and FZ: definition of intellectual content, literature research experimental studies, manuscript preparation and editing; all authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interests
All the authors have declared that in the research there was no potential conflict of interest.
Ethical approval
This study was approved by the Ethics Committee of Jinling Hospital and carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.
consent to participate
Informed consent was signed by all patients and controls.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yin, J., Chen, X., Zhang, F. et al. RMRP inhibition prevents NAFLD progression in rats via regulating miR-206/PTPN1 axis. Mamm Genome 33, 480–489 (2022). https://doi.org/10.1007/s00335-022-09945-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00335-022-09945-0